Direct Answer
190 SEC filers are classified under the Standard Industrial Classification code that describes the rare disease pharmaceuticals industry, and their latest annual reports show $454.1 billion of combined revenue and a median operating margin of -339.4%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics.
Industry Overview
Rare disease pharmaceutical companies sell treatments for orphan conditions, often with high prices and limited competition. Revenue depends on identifying patients, reimbursement and exclusivity. The first numbers to compare across companies here are patients treated and net revenue per patient, share of key therapies and pipeline.
Key Industry Metrics
- Patients treated and net revenue per patient: Number of treated patients and revenue earned from each after discounts. Small populations and high prices make both vital to growth.
- Share of key therapies: Portion of patients using a company's drug in a condition. Few treatments exist, so share shows competitive position, especially against new entrants.
- Pipeline: Candidates in development and trial stage. New approvals diversify away from a single product and extend growth.
- Exclusivity: Remaining period of market protection from orphan or patent rights. It shows how long competition is limited.
- Cash flow: Cash generated from operations. Established rare-disease sales can generate it, and it funds research and acquisitions.
Primary Macro Drivers
- Diagnosis and newborn screening: Screening at birth and better diagnosis find more patients who can be treated, which raises patients treated and revenue.
- Payer coverage: Insurers decide whether to cover costly drugs, so coverage affects patients treated and net price per patient.
- New approvals: Each approval in a rare condition adds a product with limited competition, so approvals drive revenue growth and share.
- Orphan drug incentives: Market exclusivity and tax credits protect rare disease drugs from copies for a period, which supports pricing and cash flow.
Major Risks
- Pricing scrutiny: High prices attract scrutiny from payers and lawmakers, which can lead to rebates or restrictions; watch policy proposals and net price per patient.
- Competition from gene therapy: One-time gene therapies could replace chronic treatment and reduce long-term patients; watch competing trial results and approvals.
- Concentrated product risk: Many companies rely on a few products for most revenue, so a setback moves results; watch revenue by product and pipeline.
- Safety: Serious side effects can lead to label changes or restricted use; watch regulator communications and safety updates.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Growth |
| Geographic Importance | U.S. / Global |
Rare Disease Pharmaceuticals Filers in the SEC Record
190 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification code 2834. Their latest fiscal years end between 2022 and 2026, and together they reported $454.1 billion of revenue. Median revenue growth over the prior year was 11.1%. Median operating margin was -339.4% and median net margin -202.0%. Median total liabilities were 40% of total assets, and 40 of 190 reported a profit in their latest year.
| Company | Revenue | Growth | Operating margin | Net margin | Year |
|---|---|---|---|---|---|
| Johnson & Johnson | $94.2 billion | 6.0% | n/a | 28.5% | FY 2025 |
| Eli Lilly & Co | $65.2 billion | 44.7% | n/a | 31.7% | FY 2025 |
| Pfizer Inc | $62.6 billion | -1.6% | n/a | 12.4% | FY 2025 |
| Abbvie Inc. | $61.2 billion | 8.6% | 24.6% | 6.9% | FY 2025 |
| Bristol Myers Squibb Co | $48.2 billion | -0.2% | n/a | 14.6% | FY 2025 |
| Abbott Laboratories | $44.3 billion | 5.7% | 18.2% | 14.7% | FY 2025 |
| Viatris Inc | $14.3 billion | -3.0% | -18.6% | -24.6% | FY 2025 |
| Vertex Pharmaceuticals Inc / Ma | $12.0 billion | 8.9% | 34.8% | 32.9% | FY 2025 |
The 8 largest of 190 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code.
Where to Go Next
The Rare Disease Pharmaceuticals guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Regenerative Medicine
- Rare Disease Biotechnology
- Remote Patient Monitoring
- Proteomics
- Research & Manufacturing Services
- Prosthetics
- Research Reagents
- Primary Care Platforms
Put it to work
Frequently Asked Questions
What are the main KPIs for the Rare Disease Pharmaceuticals industry?
Key performance indicators for the Rare Disease Pharmaceuticals industry include: Patients treated and net revenue per patient, Share of key therapies, Pipeline, Exclusivity, Cash flow. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Rare Disease Pharmaceuticals industry?
The Rare Disease Pharmaceuticals industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.
What are the biggest risks in the Rare Disease Pharmaceuticals industry?
The primary risks for Rare Disease Pharmaceuticals companies include: Pricing scrutiny, Competition from gene therapy, Concentrated product risk, Safety. Investors should assess each company's exposure to these factors and its track record of navigating them.